Gilead Sciences (NASDAQ:GILD) Price Target Raised to $84.00 at Barclays

Gilead Sciences (NASDAQ:GILD) had its price target hoisted by Barclays from $76.00 to $84.00 in a research report report published on Monday morning, Benzinga reports. Barclays currently has an equal weight rating on the biopharmaceutical company’s stock.

Several other analysts have also recently commented on the company. Truist Financial upped their target price on Gilead Sciences from $82.00 to $83.00 and gave the company a hold rating in a report on Thursday, August 15th. Raymond James upgraded shares of Gilead Sciences from a market perform rating to an outperform rating and set a $93.00 price target for the company in a research note on Monday, July 8th. Piper Sandler reissued an overweight rating and set a $95.00 price objective on shares of Gilead Sciences in a report on Wednesday, September 11th. Cantor Fitzgerald reiterated a neutral rating and set a $70.00 price target on shares of Gilead Sciences in a report on Monday, September 16th. Finally, Wells Fargo & Company raised Gilead Sciences from an equal weight rating to an overweight rating and raised their target price for the stock from $78.00 to $100.00 in a research report on Monday. Eleven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average target price of $84.83.

Gilead Sciences Stock Down 1.7 %

GILD stock opened at $84.67 on Monday. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $87.86. The company has a market cap of $105.49 billion, a PE ratio of 235.19, a price-to-earnings-growth ratio of 2.91 and a beta of 0.18. The business has a 50-day simple moving average of $79.54 and a 200 day simple moving average of $72.17.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. The company had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Sell-side analysts anticipate that Gilead Sciences will post 3.78 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.64%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s payout ratio is currently 855.56%.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock valued at $3,033,340 over the last three months. Insiders own 0.16% of the company’s stock.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently modified their holdings of GILD. Institute for Wealth Management LLC. boosted its holdings in Gilead Sciences by 1.9% in the second quarter. Institute for Wealth Management LLC. now owns 7,551 shares of the biopharmaceutical company’s stock worth $518,000 after acquiring an additional 142 shares in the last quarter. First Affirmative Financial Network lifted its holdings in shares of Gilead Sciences by 3.5% during the 1st quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 147 shares during the period. Insigneo Advisory Services LLC increased its position in shares of Gilead Sciences by 1.7% during the 2nd quarter. Insigneo Advisory Services LLC now owns 8,830 shares of the biopharmaceutical company’s stock valued at $661,000 after purchasing an additional 148 shares during the last quarter. MCF Advisors LLC raised its position in Gilead Sciences by 2.1% in the first quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock worth $538,000 after acquiring an additional 152 shares during the period. Finally, Westside Investment Management Inc. raised its holdings in Gilead Sciences by 0.6% in the 2nd quarter. Westside Investment Management Inc. now owns 26,526 shares of the biopharmaceutical company’s stock worth $1,826,000 after purchasing an additional 152 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.